Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Correction and maintenance study of subcutaneous injections of R744 to predialysis patients (phase III, comparative study in comparison with epoetin beta)

X
Trial Profile

Correction and maintenance study of subcutaneous injections of R744 to predialysis patients (phase III, comparative study in comparison with epoetin beta)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epoetin beta; Methoxy polyethylene glycol-epoetin beta
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 06 Jan 2009 Status changed from active, no longer recruiting to completed.
    • 09 Jun 2008 The expected completion date for this trial is now 1 Jan 2008 as reported by ClinicalTrials.gov.
    • 29 Jan 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top